Elan reveals favourable drug trials for key MS drug
http://tinyurl.com/b84zl
AFP/DDP/File Photo: Two scientists examine human brain functions. Irish pharmaceuticals giant Elan said that the latest...
Tysabri, made by the Irish drugs firm and US partner Biogen, was withdrawn in February after confirmed cases of progressive multifocal leukoencephalopathy (PML), a very rare and usually fatal disease.
"Three confirmed cases of PML were previously reported, two of which were fatal," Elan said.
Findings from their latest safety tests showed "no new confirmed cases" of the infection.
The two companies submitted Tysabri to the US
" type="hidden"> SEARCHNews | News Photos | Images | Web" type="hidden"> Food and Drug Administration at the end of last month, while the European Medicines Agency was also reviewing their application, the statement added.
0 Comments:
Post a Comment
<< Home